The Epidemiology of Revision Total Knee Arthroplasty
- PMID: 34507367
- DOI: 10.1055/s-0041-1735282
The Epidemiology of Revision Total Knee Arthroplasty
Abstract
With an expected increase in total knee arthroplasty (TKA) procedures, revision TKA (rTKA) procedures continue to be a burden on the United States health care system. The evolution of surgical techniques and prosthetic designs has, however, provided a paradigm shift in the etiology of failure mechanisms of TKA. This review can shed light on the current reasons for revision, which may lead to insights on how to improve outcomes and lower future revision risks. We will primarily focus on the epidemiology of rTKA in the present time, but we will also review this in the context of various time periods to see how the field has evolved. We will review rTKAs: 1) prior to 1997; 2) between 1997 and 2000; 3) between 2000 and 2012; and 3) in the modern era since 2012. We will further subdivide each of the sections into reasons for early (first 2 years after index procedure) versus late revisions (greater than 2 years after index procedure). In doing so, it was determined that prior to 1997, the most prevalent causes of failure were infection, patella failure, polyethylene wear, and aseptic loosening. After a major shift of failure mechanisms was described by Sharkey et al, polyethylene wear and aseptic loosening became the leading causes for revision. However, with the improved manufacturing technology and implant design, polyethylene wear was replaced with aseptic loosening and infection as the leading causes of failure between 2000 and 2012. Since that time, in the modern era of TKA, mechanical loosening and infection have taken over the most prevalent causes for failure. Hopefully, with continued developments in component design and surgical techniques, as well as increased focus on infection reduction methods, the amount of rTKA procedures will decline.
Thieme. All rights reserved.
Conflict of interest statement
M.A.M. is a board or committee member for The Knee Society and The Hip Society, receives research support from National Institutes of Health, and is on the editorial board for the Journal of Arthroplasty, Journal of Knee Surgery, Surgical Technology International, and Orthopaedics. He also receives company support from 3M, Centrexion, Ceras Health, Flexion Therapeutics, Johnson & Johnson, Kolon TissueGene, NXSCI, US Medical Innovations, Pacira, Pfizer-Lily, Skye Biologics, SOLVD Health, Smith & Nephew, Stryker, CERAS Health, MirrorAR, Peerwell, US Medical Innovations, Johnson & Johnson, RegenLab, TissueGene, Stryker, Medicus Works LLC, Up-to Date, Wolters Kluwer Health–Lippincott Williams & Wilkins, Journal of Arthroplasty, Journal of Knee Surgery, Orthopedics, Surgical Techniques International; AAHKS, Knee Society, and Hip Society. Dr. Giles R. Scuderi receives royalties and/or is a consultant for Zimmer Biomet, 3M KCI, Elsevier, Springer, Thieme, and World Scientific. He has stock options in Force Therapeutics and ROM Tech. G.R.S. is also on the editorial board for the Journal of Knee Surgery and is a board member for Operation Walk USA. All other authors have no conflicts of interest to disclose.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
